Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, double blind trial of MP29-02 nasal spray compared to placebo, azelastine hydrochloride nasal spray, and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis.

Next Previous
Trial Profile

Randomized, double blind trial of MP29-02 nasal spray compared to placebo, azelastine hydrochloride nasal spray, and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Mar 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 23 Oct 2015 According to the media release of Meda Pharmaceuticals, based on the data from this and other two trials (CTP: 37579 and 43617) Dymista nasal spray (azelastine hydrochloride/fluticasone propionate) was approved by Health Canada for the symptomatic treatment of moderate-to-severe seasonal allergic rhinitis.
  • 06 Mar 2012 Results reporting the key secondary endpoint of the 12-hour reflective Total Ocular Symptom Score presented at the 68th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
  • 05 Mar 2012 Results from this trial were presented at the American Academy of Allergy, Asthma and Immunology (AAAAI), according to a Meda media release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top